Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04905277 · ClinicalTrials.gov registry record · Phase 2
Atenolol for the Prevention of Osteoporosis (APO)
A Phase 2 study of Healthy, sponsored by Sundeep Khosla, M.D..
- Active
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
- 3
- Study locations
NCT04905277: Active Phase 2 study of Healthy, sponsored by Sundeep Khosla, M.D..
NCT04905277 is a Phase 2 study of Healthy that is active but no longer recruiting, run by Sundeep Khosla, M.D.. The registered enrollment target is 420 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (35% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04905277, a Phase 2 study of Healthy, is active but no longer recruiting, sponsored by Sundeep Khosla, M.D..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
- 3
- Study locations
Study Summary
Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.
Primary Outcome
Percent change in total hip bone mineral density (BMD) by DXA
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atenolol 50 MG
Study Locations (3)
Maine
- MaineHealth - Scarborough
Minnesota
- Mayo Clinic - Rochester
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
What the registry record for NCT04905277 still lists
NCT04905277 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04905277 reports a single indexed study location in Maine, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT04905277 about?
NCT04905277 is a clinical study titled "Atenolol for the Prevention of Osteoporosis (APO)". Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.
What is the current status of trial NCT04905277?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2021-07-27. Estimated completion is 2026-03-31.
What conditions does trial NCT04905277 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT04905277?
The interventions under investigation include: Placebo (DRUG), Atenolol 50 MG (DRUG).
Who is sponsoring clinical trial NCT04905277?
This trial is sponsored by Sundeep Khosla, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04905277 being conducted?
This trial has 3 study locations across Maine, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04905277's enrollment target sits among peer trials
420 59th of 1090 higher than 1,032 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Effects of an Antioxidant Supplement on Blood Vessel Health
RECRUITING · Phase 2
-
Effectiveness of Aquamin® in Mitigating Halitosis
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
COMPLETED · Phase 2
-
Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI